The Manufacturers Life Insurance Company Purchases Shares of 195,442 ICU Medical, Inc. $ICUI

The Manufacturers Life Insurance Company purchased a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 195,442 shares of the medical instruments supplier’s stock, valued at approximately $28,652,000.

Several other large investors also recently modified their holdings of ICUI. Allworth Financial LP acquired a new position in shares of ICU Medical during the 2nd quarter valued at $26,000. Hilton Head Capital Partners LLC acquired a new stake in ICU Medical in the fourth quarter worth $32,000. Covestor Ltd grew its holdings in ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 126 shares during the period. Strs Ohio grew its holdings in ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 300 shares during the period. Finally, Rockefeller Capital Management L.P. increased its stake in ICU Medical by 21.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 146 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, Director Elisha W. Finney sold 378 shares of ICU Medical stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total transaction of $68,977.44. Following the completion of the transaction, the director owned 4,871 shares in the company, valued at approximately $888,860.08. The trade was a 7.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ben Sousa sold 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total value of $401,220.00. Following the sale, the insider directly owned 3,076 shares of the company’s stock, valued at $548,512.32. This represents a 42.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 16,974 shares of company stock valued at $3,085,844. Insiders own 2.10% of the company’s stock.

ICU Medical Stock Performance

Shares of ICUI stock opened at $175.10 on Friday. The firm has a market capitalization of $4.38 billion, a PE ratio of 148.39, a price-to-earnings-growth ratio of 2.27 and a beta of 0.74. The firm has a fifty day simple moving average of $163.95 and a two-hundred day simple moving average of $143.89. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. ICU Medical, Inc. has a 12 month low of $112.50 and a 12 month high of $192.85.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same quarter in the prior year, the company posted $2.10 earnings per share. The business’s revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Analysts forecast that ICU Medical, Inc. will post 7.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ICUI has been the topic of several research reports. Raymond James Financial reiterated a “strong-buy” rating and set a $200.00 price objective on shares of ICU Medical in a report on Friday, August 7th. Piper Sandler raised their target price on ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Finally, Needham & Company LLC increased their price target on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $192.80.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.